Month: June 2020

Growth Capital To Fuel Surging Revenue Growth in 2020NEW YORK and TORONTO, June 19, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality for eCommerce, AR learning applications, and AR-enhanced virtual events is pleased to announce that it has closed a private placement of 1,528,036 units priced at the market price of $2.10 per unit (the “Units”) for gross proceeds of $3,208,875 (the “Offering”). Each Unit consists of one common share and one half share purchase warrant exercisable at $3.00 per share for a period of two years (the “Warrants”) and subject to acceleration provisions. The use of proceeds includes: growing sales and engineering teams, pursuing strategic M&A opportunities, and for general working capital purposes.Kashif Malik CFO of...

Makes Donations to the Equal Justice Initiative and NAACPDebuts ‘Amplifying Black Voices’ Artist Series on Nasdaq MarketSite TowerLaunches Bell Ceremony Series to Acknowledge Frontline HeroesNEW YORK, June 19, 2020 (GLOBE NEWSWIRE) — Nasdaq, Inc. announced today additional steps in its continued commitment to diversity and inclusion. Actions from the company will include cash donations to organizations fighting racial injustice and increased investment in the company’s internal programs, including professional advancement and talent acquisition, to foster a diverse and inclusive corporate culture.“The on-going health crisis and recent events we have all witnessed have magnified the injustices disproportionally impacting Black communities,” said Adena Friedman, President and Chief Executive Officer, Nasdaq. “There has been an outpouring...

Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitisDupixent included in China’s list of overseas approved drugs that meet urgent clinical needDupixent is approved in 60 countries for adults with moderate-to-severe atopic dermatitis, one of the diseases driven by type 2 inflammationPARIS and TARRYTOWN, NY – June 19, 2020 – The National Medical Products Administration (NMPA) in China has approved Dupixent® (dupilumab) for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NMPA identified Dupixent as an overseas medicine considered urgently needed in clinical practice, leading to an expedited review and approval process.“The limited treatment options in China for...

Dupixent® (dupilumab) approuvé en Chine pour le traitement de la dermatite atopique modérée à sévère de l’adulteInscription de Dupixent sur la liste des médicaments étrangers en Chine répondant à un besoin clinique urgentDupixent est approuvé dans 60 pays pour le traitement de la dermatite atopique modérée à sévère de l’adulte – une des maladies médiées par une inflammation de type 2  PARIS et TARRYTOWN (New York) – Le 19 juin 2020 – L’Agence nationale des médicaments (National Medical Products Administration, NMPA) de Chine a approuvé Dupixent® (dupilumab) pour le traitement de la dermatite atopique modérée à sévère de l’adulte non contrôlé par des traitements topiques soumis à prescription médicale ou auquel ces traitements sont déconseillés. La NMPA a identifié Dupixent comme un médicament étranger dont la Chine a un besoin urgent...

Pixium Vision selected to participate in the Next French Healthcare program organized by Business France and Bpifrance, bolstering presence in the USParis, 19 June 2020 – 07.30 am CET– Pixium Vision (Euronext Growth Paris – FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, today announces it is one of the 13 laureates selected among the most innovative French lifescience companies to take part in a US investor roadshow in October 2020, organized by Business France and Bpifrance.Pixium Vision will update investors on its plans for the bionic vision Prima System and increase awareness in the US of its exciting development and commercial plans. Recent 18-month data have shown the Prima System is able to combine natural residual...

Pixium Vision sélectionné pour participer au programme Next French Healthcare organisé par Business France et Bpifrance, intensifiant ainsi sa présence aux États-UnisParis, le 19 juin 2020 – 07h30 CET – Pixium Vision (Euronext Growth Paris – FR0011950641), une société de bioélectronique qui développe des systèmes de vision bionique innovants pour permettre aux patients qui ont perdu la vue de vivre de manière plus autonome, annonce aujourd’hui faire partie des 13 healthtech françaises les plus innovantes sélectionnées pour participer au mois d’octobre prochain, à un roadshow aux Etats-Unis organisé par Business France et Bpifrance.Pixium Vision présentera le plan de développement clinique et commercial du Système Prima à de potentiels investisseurs américains sur la base de récentes données cliniques sur 18 mois...

OSLO, Norway, June 19, 2020 (GLOBE NEWSWIRE) — Opera GX, the world’s first gaming browser, is introducing new features including Discord support and a Hot tabs killer. It can also force brightly-designed pages to become dark to stop that nighttime glare.–       Opera believes that more than one billion PC gamers around the world deserve a browsing experience tailored to their needs–       Opera GX remains the only web browser made specifically for people who love and play video games and experienced a 121% growth in monthly users since end of 2019   With 1.3 billion PC gamers around the world and the gaming industry surpassing the movie and music business in revenue, Opera GX [NASDAQ: OPRA] remains the only PC browser designed with gamers’ needs in mind. The browser has many useful features including Twitch integration,...

LEXINGTON, Mass. and AMSTERDAM, June 19, 2020 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first two patients in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease have been treated. The Phase I/II study is a double-blind, randomized clinical trial being conducted in the United States, with now one patient treated with AMT-130, and one patient who received the imitation surgery.“For years, uniQure has had an unwavering commitment to advance this first-in-human AAV gene therapy for Huntington’s disease into clinical testing, and this moment marks an important milestone for our company now that we have two AAV gene therapy candidates in clinical development,” said Matt...

Dalius Gesevicius, Managing Director of Panevezio statybos trestas AB, leaves the company by the mutual decision. Based on the decision taken by the Board, from June 23rd the position of Managing Director will be taken over by Egidijus Urbonas who has been managing the companies of the PST Group – Metalo meistrai UAB and Hustal UAB.More information:Managing DirectorDalius GeseviciusTel.: (+370 45) 505 503